Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 3/20 | 0.69 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.69 |
| ▸ | TNF | P01375 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5941456 | 1.00 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL29840774 | 1.00 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL476983 | 1.00 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL7746552 | 0.93 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL14983194 | 0.93 | MEN1 (0.63) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL14983193 | 0.93 | MEN1 (0.63) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL18790608 | 0.93 | MEN1 (0.63) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL9924689 | 0.92 | TP53 (0.67) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL8267912 | 0.92 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4445016 | 0.91 | TNF (0.69) | PDE4APDE4BPDE4CPDE4DTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2555769-B1 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | AMGEN EUROPE GMBH (CH) | 2022-01-12 | — | — | EP | disclosed |
| US-10994082-B2 | Inhaler counter | ASTRAZENECA AB (SE) | 2021-05-04 | — | — | US | disclosed |
| US-20190175849-A1 | INHALER COUNTER | BANG & OLUFSEN MEDICOM A/S (DK) | 2019-06-13 | — | — | US | disclosed |
| US-20180339119-A1 | INHALER | BANG & OLUFSEN MEDICOM A/S (DK) | 2018-11-29 | — | — | US | disclosed |
| EP-2755707-B1 | INHALER | ASTRAZENECA AB (SE) | 2018-11-14 | — | — | EP | disclosed |
| EP-3345644-A1 | INHALER | Astrazeneca AB (SE) | 2018-07-11 | — | — | EP | disclosed |
| EP-2755708-B1 | INHALER | ASTRAZENECA AB (SE) | 2018-05-09 | — | — | EP | disclosed |
| EP-2448623-B1 | DISPENSER AND METHOD FOR ENTRAINING POWDER IN AN AIRFLOW | ASTRAZENECA AB (SE) | 2017-12-20 | — | — | EP | disclosed |
| EP-2341968-B1 | A BREATH ACTIVATED INHALER | ASTRAZENECA AB (SE) | 2017-05-10 | — | — | EP | disclosed |
| US-9408831-B2 | Methods for treating respiratory viral infection | CELGENE CORPORATION (US) | 2016-08-09 | — | — | US | disclosed |
| WO-2008096111-A1 | COMBINATIONS OF BETA- 2 -ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096121-A1 | COMBINATIONS OF BETA-2-ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | WO | disclosed |
| US-20060247296-A1 | Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide | CELGENE CORPORATION | 2006-11-02 | — | — | US | disclosed |
| CN-1738614-A | Compositions comprising (-) -3- (3, 4-dimethoxy-phenyl) -3- (1-oxo-1, 3-dihydro-isoindol-2-yl) -propionamide and methods of use thereof | CELGENE CORP (US) | 2006-02-22 | — | — | CN | disclosed |
| CN-1738613-A | Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide | CELGENE CORP (US) | 2006-02-22 | — | — | CN | disclosed |
| CN-1713905-A | Selective cytokine inhibitory drugs for treating myelodysplastic syndrome | CELGENE CORP (US) | 2005-12-28 | — | — | CN | disclosed |
| EP-1569599-A2 | METHODS OF USIG AND COMPOSITIONS COMPRISING (-)-3-(3,4-DIMETHOXY-PHENYL)-3-(1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PROPIONAMIDE | CELGENE CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040167199-A1 | Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide | CELGENE CORPORATION | 2004-08-26 | — | — | US | disclosed |
| WO-2004054501-A2 | METHODS OF USIG AND COMPOSITIONS COMPRISING (-)-3-(3,4-DIMETHOXY-PHENYL)-3-(1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PROPIONAMIDE | CELGENE CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004054501-A2 | METHODS OF USIG AND COMPOSITIONS COMPRISING (-)-3-(3,4-DIMETHOXY-PHENYL)-3-(1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PROPIONAMIDE | CELGENE CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167199-A1 | Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide | PDE4A, PDE3A, PDE2A | PDE4A 1/4885PDE4B 4/4885PDE4C 5/4885 |
| US-20060247296-A1 | Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide | PDE4A, PDE3A, PDE2A | PDE4A 1/4885PDE4B 4/4885PDE4C 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.